This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
RESMETIROM — Description, Dosage, Side Effects | PillsCard
OTC
RESMETIROM
80 mg/1, Tablet, coated
INN: RESMETIROM
Data updated: 2026-04-26
Available in:
🇬🇧🇵🇹
Form
TABLET, COATED
Dosage
80 mg/1
Route
ORAL
Storage
—
About This Product
Manufacturer
Madrigal Pharmaceuticals, Inc.
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Source
OPENFDA_NDC
USDailyMed:Resmetirom
A05BA11(WHO)
US:℞-onlyEU:Rx-only
2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
920509-32-6
15981237
DB12914
RE0V0T1ES0
D11602
ChEMBL3261331
DTXSID601352610
Interactive image
CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N
Resmetirom, sold under the brand nameRezdiffra, is a medication used to treat a form offatty liver disease. Specifically it is used in the treatment of noncirrhoticmetabolic dysfunction associated steatohepatitis(MASH) (formerly known as nonalcoholic steatohepatitis NASH).It is structurally similar to thethyroid hormonetriiodothyronineand acts as anagonistof thethyroid hormone receptor beta(NR1A2).
The most common side effects include diarrhea and nausea.
Resmetirom was approved for medical use in the US in March 2024,and in the European Union in August 2025.The USFood and Drug Administrationconsiders it to be afirst-in-class medication.
